The answer depends on the defect, not the symptom

Most people arrive at this question the same way: knee pain, an MRI result, and a consultant who has mentioned both an injection and a surgical procedure. The natural impulse is to weigh one against the other as a matter of preference — less invasive versus more thorough, quicker recovery versus longer-term fix. That framing, though understandable, misses what actually drives the decision.

A focal cartilage defect is a contained patch of full- or partial-thickness cartilage loss — structurally distinct from the widespread surface degradation of generalised osteoarthritis. It has different biology, different natural history, and its own treatment logic. Left untreated, articular cartilage cannot self-repair: the tissue is avascular, and defects that exceed roughly 1 cm² in size may enlarge and progress towards osteoarthritis over time.

The primary discriminators are found on MRI, not in a symptom checklist: the grade of the defect (ICRS/Outerbridge III–IV being the typical threshold for active intervention), its size, whether the underlying bone layer is involved, and the condition of the joint as a whole. Generalised osteoarthritis, uncorrected mechanical malalignment, and significant subchondral bone damage affect suitability for both an injectable scaffold and surgical cartilage repair — and need to be identified before any treatment decision is made.

Neither pathway is universally superior. An injectable collagen scaffold suits certain defect profiles and patient circumstances; surgical cartilage repair suits others. The sections below set out which MRI and clinical features point toward each.

What ChondroFiller injection actually does inside the joint

Unlike a corticosteroid, hyaluronic acid injection, or PRP, ChondroFiller is not targeting pain signals or joint lubrication. It is a structural material — an acellular Type I collagen scaffold delivered into the defect site during an outpatient, ultrasound-guided appointment.

Think of it like the temporary framework a builder erects before a wall can go up: the scaffold itself does not form the final structure, but it creates the conditions in which construction can happen. Once placed under ultrasound guidance, the collagen material self-gels rapidly within the defect, bonding to the surrounding cartilage and forming a stable matrix. 'Acellular' here simply means no donor or laboratory-grown cells are introduced — the scaffold relies entirely on the patient's own biology to do the rest.

What it aims to do is act as a chemotactic environment: a signal-rich structure that may encourage the body's endogenous repair cells to migrate in from the adjacent tissue. Those cells — including mesenchymal stem cells from the surrounding joint — may then undergo chondrogenic differentiation, potentially beginning to lay down new cartilage-like tissue within the matrix. Published series suggest this process consolidates over the months following the outpatient procedure, though the degree of tissue regeneration will vary between patients.

This mechanism places ChondroFiller in a fundamentally different category from symptomatic injections. Hyaluronic acid supplements the joint's natural lubricant; corticosteroids reduce acute inflammation; PRP introduces growth-factor-rich plasma to modulate the local environment. None of those approaches addresses the structural architecture of a focal defect. ChondroFiller's CE Class III designation — the same regulatory classification applied to active structural implants — reflects that distinction formally, not just conceptually.

What the published evidence shows for the injection route

Published data on the ChondroFiller injection pathway come from prospective cohort series rather than large randomised trials — an honest starting point that shapes how the numbers should be read.

Across the available series, clinically meaningful improvements on validated outcome measures — including the IKDC and Lysholm knee scoring scales — have been reported and sustained beyond 12 months. One published cohort confirmed statistically significant gains on both scales at three, six, and twelve months, with the trajectory of improvement appearing to plateau around the six-to-twelve-month mark, suggesting that most of the functional benefit consolidates within the first year following the outpatient procedure. Patient satisfaction rates across published series have generally been high, though the individual cohorts involved remain modest in size.

Two limitations deserve straightforward acknowledgement. First, the absence of a head-to-head randomised controlled trial comparing ChondroFiller injection directly with surgical cartilage repair is a genuine gap in the literature. The absence of an RCT is not unusual for orthopaedic interventions — including some that are now widely adopted — but it does mean that comparative claims between the injection pathway and surgery cannot be made on that level of evidence. Second, durability data beyond three to five years following injection-delivered placement are limited; whether gains hold or attenuate over longer time horizons is not yet established.

Published series nonetheless provide a reasonable signal for clinical decision-making, provided both the encouraging outcomes and the evidence boundaries are weighed together.

When surgical cartilage repair carries stronger evidence

Surgical cartilage repair carries the largest accumulated trial evidence for contained focal defects, and for specific presentations it remains the better-evidenced pathway — a fact worth stating plainly before weighing alternatives.

The established surgical techniques span a spectrum. Microfracture — drilling or perforating the subchondral bone to stimulate a marrow-derived repair response — is widely used for smaller lesions, typically below 2 cm², but the tissue it produces is fibrocartilage rather than the hyaline cartilage that lines a healthy joint. Fibrocartilage is mechanically inferior and may be less durable under repeated load. Autologous chondrocyte implantation and its matrix-assisted variant (MACI) address larger defects and have the potential to generate more hyaline-like tissue, but the process is multi-stage: a preliminary arthroscopic harvest collects a small cartilage biopsy for laboratory expansion before a second procedure implants the cultured cells. Both stages typically involve general anaesthetic and a structured post-operative rehabilitation period.

A 2024 prospective multicentre randomised controlled trial (n=92, ICRS Grade 3–4 femoral condyle lesions) found that a biphasic scaffold implant was non-inferior to microfracture at twelve months on the IKDC scale, while arthroscopic assessment showed more fully regenerated cartilage in the scaffold group — suggesting that newer surgical scaffold approaches are improving on traditional marrow stimulation in tissue quality, if not yet in functional score advantage.

A separate 2025 registry study (n=217, mean follow-up 6.8 years) confirmed that patients aged 50–69 achieved equivalent Lysholm and pain outcomes to those under 50 following surgical AMIC repair, with no statistically significant difference between groups. Chronological age above 50, taken alone, does not appear to be a contraindication for surgical cartilage repair.

Surgical repair is presented here as the established alternative pathway for orientation — not as the described injection-based service.

The clinical factors that steer the decision

Defect grade and size on MRI is the natural starting point. A contained, high-grade focal lesion — where the surrounding cartilage is largely intact — is the primary indication for both the injection route and surgical cartilage repair. Generalised joint-surface degradation, or defects that extend well beyond a contained area, may reduce what either pathway can realistically offer.

Bone involvement adds a layer that MRI makes visible. Where a lesion extends through the cartilage surface into the subchondral bone beneath it, an approach capable of addressing that deeper layer may be more appropriate than one focused on the cartilage surface alone. This is a specific reason why imaging review, rather than symptoms alone, is the basis for any treatment decision.

Joint alignment is less obvious but consequential. An uncorrected mechanical fault — the leg tracking unevenly through the knee under load — concentrates force on the very area being treated and can undermine lasting benefit from either cartilage repair pathway. Alignment problems sometimes need to be addressed before or alongside any repair attempt.

Regenerative capacity and treatment goals interact in a practical way. The injection route relies on the body recruiting its own cells into the scaffold to build new tissue; this mechanism tends to suit patients where coverage of a broader joint surface is the priority, or where the clinical picture makes surgical intervention less appropriate. Where the goal is concentrated, site-specific tissue repair — particularly in active patients with a clearly bounded focal defect and well-preserved surrounding cartilage — surgical placement targets that biology more directly.

Recovery logistics are a legitimate factor too. An ultrasound-guided outpatient injection and a surgical day-case under general anaesthetic carry different immediate demands, and some patients face practical or medical reasons that make one route more accessible than the other.

None of these factors operates in isolation — a small lesion with poor alignment tells a different story from a larger defect in a mechanically sound joint. An MRI review and a specialist assessment are the right context in which to weigh them for any individual situation.

Finding out if the injection route suits your defect

Knowing whether the injection route is appropriate requires structured review rather than symptom description alone. A suitability assessment typically covers existing MRI imaging, symptom history, activity demands, and overall joint condition — the same factors discussed above, applied to an individual's specific scan rather than in general terms. For patients who want a preliminary view of whether their clinical picture fits this pathway before consulting a specialist, an online suitability assessment is available at amsk.co.uk.

Part of the formal assessment process is ruling candidates out. The clinical factors covered in the preceding section — alignment, bone-layer involvement, and the extent of joint-surface wear — are weighed against the individual's imaging. Patients directed toward a different pathway at that stage are not encountering a setback; the filtering is part of what makes the pathway appropriate for those who do proceed.

For patients with a focal defect in a mechanically sound joint, the ultrasound-guided, outpatient nature of the treatment means that assessment and a treatment decision can often proceed without a surgical referral — a practical distinction for those weighing clinical suitability alongside recovery implications.

1. [1] Biphasic cartilage repair implant versus microfracture in the treatment of focal chondral and osteochondral lesions of the knee: a prospective, multi-center, randomized clinical trial. (2024). https://doi.org/10.1186/s10195-024-00802-1 https://doi.org/10.1186/s10195-024-00802-1
2. [2] Patients aged 50 to 69 years show comparable outcomes with those aged under 50 years following AMIC for focal chondral defects in the knee. (2025). https://doi.org/10.1302/0301-620X.107B10.BJJ-2024-1397.R2 https://doi.org/10.1302/0301-620X.107B10.BJJ-2024-1397.R2
3. [3] Collagen Type II-Based Injectable Materials for In situ Repair and Regeneration of Articular Cartilage Defect. (2024). https://doi.org/10.34133/bmr.0072 https://doi.org/10.34133/bmr.0072